Abbvie

P16-489 | DEVOTE

NCT03310190

Devote

Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice (DEVOTE)

Status:

Closed to Accrual

26459-200.png

Observational

Phase

Line of Therapy.png

N/A

Line of Therapy

Disease Stage.png

Any Stage

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Venetoclax

Antineoplastic Agent; BCL-2 Inhibitor (p.o.)

Treatment Arms

o Participants receiving venetoclax